| oxaliplatin / Generic mfg. |
NCT00271271: Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients |
|
|
| Completed | 2 | 40 | Europe | oxaliplatine / gemcitabine / Vinorelbine | Sanofi | Non Small Cell Lung Cancer | | 10/06 | | |
NCT00316433: Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer |
|
|
| Terminated | 2 | 24 | US | Irinotecan (CPT-11), Oxaliplatin (Eloxatin) | Swedish Medical Center, Sanofi-Synthelabo | Small Cell Lung Cancer | | 01/07 | | |
NCT00217282: Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 45 | US | oxaliplatin, gemcitabine, bevacizumab | Mt. Sinai Medical Center, Miami, Sanofi-Synthelabo, Genentech, Inc. | Non-Small Cell Lung Cancer | 06/07 | 03/08 | | |
NCT00612677: Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem |
|
|
| Terminated | 2 | 1 | US | Oxaliplatin, Eloxatin™, Pemetrexed, Alimta™ | H. Lee Moffitt Cancer Center and Research Institute, Sanofi | Lung Cancer | 01/08 | 01/08 | | |
NCT00251524: A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC |
|
|
| Completed | 2 | 69 | US | Bevacizumab, Oxaliplatin, Pemetrexed, Avastin | Veeda Oncology, Sanofi, Eli Lilly and Company, Genentech, Inc. | Non-Small Cell Lung Cancer | 05/09 | 05/09 | | |
NCT00145418: Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer |
|
|
| Terminated | 2 | 15 | US | Oxaliplatin + Docetaxel, Eloxatin | Oncology Specialists, S.C., Sanofi-Synthelabo | Carcinoma, Non-Small-Cell Lung | 08/09 | 03/10 | | |
NCT00240097: Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) |
|
|
| Completed | 2 | 30 | US | Intervention A: Irinotecan; Oxaliplatin; Neulasta, Camptosar, Eloxatin, Pegfilgrastim, Intervention B: Etoposide; Carboplatin; Neulasta, VP-16, Etopophos®, Vepesid®, Taxol, Paraplatin | University of Alabama at Birmingham, Sanofi-Synthelabo, Amgen | Non-Small Cell Lung Cancer | 06/10 | 06/10 | | |
NCT00356122: Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Completed | 2 | 53 | US | Docetaxel, Oxaliplatin, Bevacizumab | Sanofi, Genentech, Inc. | Non-Small Cell Lung Cancer | 08/10 | 08/10 | | |
| Completed | 2 | 41 | Europe | Docetaxel, Taxotere, oxaliplatin, CDDP, cetuximab, Erbitux, surgery | Wolfgang Hilbe, Merck Sharp & Dohme LLC, Sanofi, TAKO - Tiroler Arbeitskreis Onkologie | Carcinoma, Non-small-cell Lung | 06/11 | 06/11 | | |
| Completed | 2 | 33 | RoW | Belotaxel, Docetaxel, Belloxa, Oxaliplatin | Chonnam National University Hospital, Chong Kun Dang Pharmaceutical | Non-Small Cell Lung Cancer | 01/13 | 01/13 | | |
